Angiogenic factor VEGF and its relationship with biological prognostic markers in chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic Lymphocytic Leukemia (CLL) is a heterogeneous malignancy, making prognosis prediction challenging.
• Identifying reliable prognostic factors is crucial for effective patient management in CLL.
• Existing prognostic markers require further validation and correlation with novel factors.

Purpose of the Study:

• To evaluate Vascular Endothelial Growth Factor (VEGF) as a prognostic indicator in CLL.
• To correlate VEGF levels with established prognostic factors such as CD38 and soluble p53 (sP53).
• To examine these correlations across different stages of the modified Rai staging system.

Main Methods:

• Retrospective analysis of CLL patient data.
• Measurement of CD38 expression, sP53 levels, and VEGF concentrations.
• Statistical correlation analysis between these markers and disease staging.

Main Results:

• Significantly higher median values of CD38, sP53, and VEGF were observed in intermediate and high-risk CLL subgroups compared to the low-risk subgroup.
• A strong positive correlation was found between CD38 expression and VEGF levels across all patient subgroups.
• A positive correlation between VEGF and sP53 was significant only in the high-risk CLL subgroup.

Conclusions:

• The strong association between CD38 and VEGF suggests that angiogenic factors may drive aggressive clinical behavior in CD38-positive CLL.
• VEGF emerges as a potential prognostic biomarker in CLL, particularly in conjunction with CD38 status.
• These findings provide a scientific rationale for exploring antiangiogenic therapies targeting VEGF in specific CLL patient populations.